Biomarkers in paediatric research and practice

B P Lanphear1, C F Bearer

  • 1Cincinnati Children's Environmental Health Center, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA. bruce.lanphear@chmcc.org

Insights

Children's health is significantly impacted by their environment. Environmental factors, alongside host susceptibility, are major contributors to both infectious diseases and emerging health issues like asthma and cancer.

Area of Science:

  • Environmental Health
  • Pediatric Medicine
  • Epidemiology

Background:

  • Infectious agents are a primary cause of global mortality and disability.
  • Emerging childhood morbidities such as asthma, behavioral issues, and cancer are increasingly linked to environmental exposures.
  • The complex interplay between environmental factors and individual susceptibility is crucial for understanding disease risk.

Purpose of the Study:

  • To highlight the critical role of environmental factors in children's health outcomes.
  • To underscore the connection between environmental influences and both infectious and non-infectious diseases in children.
  • To emphasize the need for further research into environmental risk factors and host interactions.

Main Methods:

  • Review of existing literature on environmental impacts on child health.
  • Analysis of epidemiological data linking environmental exposures to disease.
  • Synthesis of current understanding regarding environmental factors and host susceptibility.

Main Results:

  • Environmental factors are a dominant determinant of children's health.
  • Industrial pollutants and other environmental influences are associated with conditions like asthma, intellectual impairments, behavioral problems, and cancer.
  • Infectious diseases remain a leading cause of death and disability worldwide.

Conclusions:

  • Environmental exposures significantly influence children's health, contributing to both infectious and chronic diseases.
  • Understanding the interaction between environmental factors and host susceptibility is key to preventing childhood disability and death.
  • Further investigation into environmental risk factors is essential for improving pediatric health outcomes.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...